With over 127,779 actively licensed NHP products in Canada, the market is proof that the system works — when applications are done right. But for every product sitting on a pharmacy shelf with a valid NPN, there are countless others that stalled, were returned, or were outright rejected during the review process.
Health Canada's Natural and Non-prescription Health Products Directorate (NNHPD) does not publish a single consolidated rejection rate, but experienced regulatory professionals know the deficiency notices that show up again and again. Whether you're submitting your first product or your fiftieth, understanding these patterns is the difference between a smooth approval and months of back-and-forth.
Here are the ten most common reasons NHP applications are rejected or issued deficiency notices — and what you can do about each one.
1. Health Claims That Fall Outside Approved Monograph Language
This is the single most frequent source of deficiency notices. Health Canada assesses claims against its library of 249 monographs, and the approved wording is not a suggestion — it is a ceiling.
Applicants routinely paraphrase claim language, combine elements from different monographs, or use marketing-friendly phrasing that diverges from what Health Canada has approved. For example, a claim like "boosts immune function" will be rejected where the monograph requires precise language such as "helps maintain immune function."
What to do: Pull the exact wording from the applicable monograph and use it verbatim. If your product makes both traditional and modern claims, review the multi-ingredient claim attribution rules carefully — Health Canada requires that traditional use claims name the specific ingredient and the recognised system of medicine (e.g., "Echinacea is traditionally used in Herbal Medicine to help relieve cold symptoms") unless all medicinal ingredients originate from the same traditional system and only traditional claims are made.
2. Unsupported Combination of Medicinal Ingredients
A multi-ingredient formulation is not simply the sum of its parts. Health Canada evaluates whether the combination itself is supported — not just the individual ingredients in isolation. If you are combining ingredients where no monograph covers the blend, you will need published clinical evidence to support the combination's safety and efficacy.
This catches many brands off guard, particularly those building complex blends of botanicals, minerals, and amino acids. With 6,210 unique medicinal ingredients licensed across the Canadian market, the ingredient-level data exists — but combination-level support is a separate requirement.
3. Incorrect or Missing Dosage Form Classification
Canada's NHP regulations are specific about dosage forms, and the classification you select has downstream implications for evidence requirements, labelling, and directions for use. Capsule products account for 38,994 licensed products — the most common form on the market — but applicants still regularly confuse hard capsules, soft capsules, and capsule sub-classifications.
Similarly, products submitted as "liquid" when they meet the definition of "oral drops" — or vice versa — generate avoidable deficiencies. Granules and powders are likewise frequently misclassified, particularly when the product is reconstituted before use.
What to do: Map your physical dosage form to Health Canada's controlled vocabulary before submission, not after.
4. Quantity of Medicinal Ingredient Outside Monograph Range
A monograph specifies not just what an ingredient can claim, but how much of it is permitted per dose. Submitting a Vitamin D product at a dose that exceeds the monograph maximum — or fails to meet the minimum for a specific indication — will result in a deficiency, even if Vitamin D appears in 9,445 licensed products and seems like the most straightforward submission imaginable.
The same applies to popular ingredients like Vitamin C (found in 10,828 licensed products) and Magnesium (7,920 licensed products). High market prevalence does not mean any dose is acceptable for any claim.
5. Inadequate Evidence for Non-Monograph Claims
When a product makes a claim not covered by an existing monograph, applicants must submit product-specific evidence — typically peer-reviewed clinical studies, systematic reviews, or pharmacopoeial references. Health Canada applies a benefit-risk framework, and the level of evidence required scales with the boldness of the claim.
Many applicants underestimate what "adequate" means here. A handful of in vitro studies will not support a clinical efficacy claim. Health Canada expects human clinical data where the claim implies a measurable therapeutic outcome.
6. Safety Concerns Triggered by Ingredient Interactions or Populations at Risk
Even when efficacy evidence is solid, Health Canada may issue a deficiency or reject an application on safety grounds. This is especially common for products intended for use by pregnant or breastfeeding individuals, children, or populations with chronic conditions.
Required risk information — cautions, warnings, contraindications, and known adverse reactions — must all appear on the label in the format Health Canada prescribes. Monographs specify these in detail. For example, the WORKOUT SUPPLEMENTS monograph lists 37 cautions alongside its 39 approved uses — one of the highest caution loads of any Health Canada monograph. Missing even a subset of required safety statements will generate a deficiency.
7. Labelling That Does Not Meet Regulatory Format Requirements
The NHP Regulations prescribe exactly how a label must be structured: what information goes where, in what language, in what type size, and with what prominence. Common labelling deficiencies include:
- Recommended dose expressed in unclear or ambiguous terms
- Missing or incorrectly formatted NPN/DIN-HM block
- Non-medicinal ingredients listed incompletely or out of required order
- Directions for use that do not match the submitted evidence
- Missing duration of use statements where required by monograph
A product with a strong evidence package can still be rejected for a label that does not meet these format requirements.
8. Incomplete or Inconsistent Product Licence Application (PLA) Data
The data fields within a Product Licence Application must be internally consistent. A claim stated in one section must align with the dosage, ingredient quantity, and population fields in every other section. Inconsistencies — even minor ones — trigger deficiency notices that require full resubmission of corrected documentation.
This is particularly problematic for applicants managing large product portfolios, where copy-paste errors or version control failures between products create contradictions within a single application.
9. Improper Use of Traditional Use Claims
Traditional use claims are governed by specific evidentiary and labelling rules that many applicants misapply. Health Canada accepts traditional use evidence — typically 50 or more years of documented use, with at least 15 years in Canada — but that evidence must be properly cited and the claim must be correctly attributed.
A claim like "traditionally used in Herbal Medicine to help relieve minor burns including sunburn" is approved language — but using it without the corresponding traditional use evidence on file, or applying it to an ingredient not covered by that evidence, will fail review. Likewise, omitting the required reference to the traditional system of medicine (Herbal Medicine, Traditional Chinese Medicine, Ayurveda, etc.) when the product includes both traditional and modern claims is a frequent and avoidable error.
10. Manufacturer or Site Licensing Deficiencies
Even a flawless PLA can be held up if the manufacturing site is not properly licensed under Canada's Site Licensing framework. Health Canada requires that all sites involved in the manufacture, packaging, labelling, and importation of NHPs hold a valid Site Licence with the appropriate activities listed.
If your contract manufacturer's Site Licence does not cover the dosage form or activity relevant to your product, the application cannot proceed. This is especially common for brands sourcing from international manufacturers who may hold licences with activity scopes that do not align with the Canadian product being registered.
The Pattern Behind the Deficiencies
Most NHP rejections are not the result of a genuinely unsafe or inefficacious product. They are the result of documentation that does not precisely match what Health Canada's review process requires. The regulatory framework is detailed, but it is navigable — if you know exactly what to look for before you submit.
Check Your Product
BareGold's AI-powered NHP compliance engine cross-references your product formulation, claims, and dosage data against Health Canada's live LNHPD and NHPID databases — including all 249 monographs and the full library of licensed ingredients — before you submit.
Identify deficiencies in your application before Health Canada does. Start your free review at productcompliance.ca and submit with confidence.